Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal has one working extract — 505(b)(2) literature-to-product bridge table — after an AdCom briefing document that overstates subgroup findings. Regulatory-affairs lead in a safety team sitting on a new disproportionate signal has 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings. If that extract cannot support to drop a secondary, the only defensible Pharma & Life Sciences CMC and Development Pathways output is hold.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once an AdCom briefing document that overstates subgroup findings is lined up to the same Pharma & Life Sciences population. 2. 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after an AdCom briefing document that overstates subgroup findings; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for regulatory-affairs lead in a safety team sitting on a new disproportionate signal. 4. 505(b)(2) literature-to-product bridge table is missing the fact regulatory-affairs lead needs after an AdCom briefing document that overstates subgroup findings; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.